My Cart

CD34

CD34 Overview

English NameHematopoietic progenitor cell antigen CD34Approved Drugs1
Drugs in Clinical Trials12Target SynonymCD34,CD34 Molecule,CD34 Antigen,Hematopoietic Progenitor Cell Antigen CD34,Antigens, CD34
Highest Development StageApproved
English NameHematopoietic progenitor cell antigen CD34
Target SynonymCD34,CD34 Molecule,CD34 Antigen,Hematopoietic Progenitor Cell Antigen CD34,Antigens, CD34
Approved Drugs1
Drugs in Clinical Trials12
Highest Development StageApproved

CD34 Product List

  • Product Category

    Protein (3)Antibody (1)

  • Product Status

    Launched (4)

  • Species

    Human (3)Mouse (1)

  • Tag

    His Tag (2)His Tag & Avi Tag (1)- (1)

  • Conjugate

    Unconjugated (1)Biotin-labeled (1)PE Labeled (2)

CD34 Background

CD34 molecule is a cluster of differentiation molecule present on certain cells within the human body. It is a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells to bone marrow extracellular matrix or directly to stromal cells. As a ~ 110 kDa monomeric cell surface antigen, CD34 is highly glycosylated with nine potential N-linked and numerous potential O-linked glycosylation sites in its extracellular domain. The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show expression on early hematopoietic and vascular-associated tissue. CD34 is also an important adhesion molecule and is required for T cells to enter lymph nodes. It is expressed on lymph node endothelia whereas the L-selectin to which it binds is on the T cell. It was indicated that CD34 is a phosphorylation target for activated PKC, and couples to the hematopoietic adapter protein CrkL, which were involved in CD34 signaling pathways. CD34 is abberantly expressed in many kinds of tumors and is implicated in leukemogenesis.

CD34 Synonyms

CD34,RP11-328D5.2

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
CLBS-12CLBS-12Phase 2 ClinicalCaladrius Biosciences IncAtherosclerosis; Ischemia; Thromboangiitis Obliterans
Details
Retroviral ADA-transduced CD34+ cells (NHGRI/UCLA)Phase 2 ClinicalUcla Biomedical LibraryAdenosine deaminase deficiency
Details
CD34+ bone marrow stem cells (University of California)Phase 2 ClinicalThe University Of California DavisDiabetic Retinopathy; Macular Degeneration; Retinal Vein Occlusion; Retinitis Pigmentosa
Details
Autologous peripheral blood stem cell therapy (CellProthera)Phase 2 ClinicalCellprotheraMyocardial Infarction
Details
CD34 stem cell therapy (LA Childrens Hospital)Phase 2 ClinicalChildren'S Hospital Of Los AngelesHeart Failure; HIV Infections
Details
Stem cell therapeutics (ExCellThera)ECT-002; ECT-003; ECT-005; UM171 + UM092; UM171 + UM390Phase 2 ClinicalExcellthera IncLeukemia, Myeloid, Acute
Details
Lentiviral vector transduced CD34+ cells TherapyPhase 2 ClinicalGreat Ormond Street Hospital For Children Nhs Foundation TrustGranulomatous Disease, Chronic
Details
Cord blood stem cells(Tatcitus Therapeutics/Mount Sinai Health System)HSC-100Phase 1 ClinicalIcahn School Of Medicine At Mount Sinai, Tatcitus TherapeuticsHematologic Neoplasms; Hodgkin Disease; Leukemia; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
shRNA-Modified CD34 Cell TherapyKL-AI20Phase 1 ClinicalKanglin Biotech (Hangzhou) Co LtdHIV Infections
Details
Alpha-galactosidase A stem cell therapy (University Health Network/Ozmosis)Phase 1 ClinicalUniversity Health Network (Uhn)Fabry Disease
Details
Autologous CD34+ Cells Therapy (Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd)GMCN-508APhase 1 ClinicalZhongji Zhiyao (Nanjing) Biotechnology Co Ltdalpha-Thalassemia
Details
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion(German Cancer Research Center)Phase 1 ClinicalGerman Cancer Research Center (Dkfz)Leukemia, Myeloid, Acute
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Anti-CD34 mab-sirolimus (OrbusNeich)ApprovedOrbusneichCoronary RestenosisOrbusneich2013-01-01Coronary Artery Disease; Coronary Restenosis
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information